



Navigating Precision Medicine In Bladder Cancer

Optimizing the Identification and Selection of Patients for Immunotherapy

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin*. 2018;68(1):7-30.
2. Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. *Sci Rep*. 2018;8(1):1129.
3. Svatek RS, Hollenbeck BK, Holmäng S, et al. The economics of bladder cancer: costs and considerations of caring for this disease. *Eur Urol*. 2014;66(2):253-262.
4. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol*. 2013;63(2):234-241.
5. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. *J Natl Cancer Inst*. 2011;103(2):117-128.
6. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. *JAMA*. 2011;306(7):737-745.
7. Ramirez D, Gupta A, Canter D, et al. Microscopic haematuria at time of diagnosis is associated with lower disease stage in patients with newly diagnosed bladder cancer. *BJU Int*. 2016;117(5):783-786.
8. Bruyninckx R, Buntinx F, Aertgeerts B, Van Casteren V. The diagnostic value of macroscopic haematuria for the diagnosis of urological cancer in general practice. *Br J Gen Pract*. 2003;53(486):31-35.
9. Elias K, Svatek RS, Gupta S, Ho R, Lotan Y. High-risk patients with hematuria are not evaluated according to guideline recommendations. *Cancer*. 2010;116(12):2954-2959.
10. Chang SS, Boorjian SA, Chou R. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. *J Urol*. 2016;196(4):1021-1029.
11. Babjuk M, Böhle A, Burger M, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. *Eur Urol*. 2017;71(3):447-461.
12. National Comprehensive Cancer Network. Bladder Cancer. Version 5. 2018. Available at https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed September 16, 2018.
13. Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. *Hematol Oncol Clin North Am*. 2015;29(2):237-252.
14. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. *Eur Urol*. 2013;63(2):234-241.
15. Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. *Eur Urol*. 2018;73(4):560-569.
16. Alfred Witjes J, Lebet T, Compérat EM, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. *Eur Urol*. 2017;71(3):462-475.
17. Compérat EM, Burger M, Gontero P, et al. Grading of Urothelial Carcinoma and The New "World Health Organisation Classification of Tumours of the Urinary System and Male Genital Organs 2016". *Eur Urol Focus*. 2018 Jan 20. [Epub ahead of print]
18. Herr HW. Role of repeat resection in non-muscle-invasive bladder cancer. *J Natl Compr Canc Netw*. 2015;13(8):1041-1046.



Navigating Precision Medicine In Bladder Cancer

Optimizing the Identification and Selection of Patients for Immunotherapy

19. Divrik RT, Yildirim U, Zorlu F, Ozen H. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. *J Urol*. 2006;175(5):1641-1644.
20. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. *Eur Urol*. 2010;58(2):185-190.
21. Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: A systematic review. *Eur Urol*. 2018;73(6):925-933.
22. Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, endpoints and clinical trial designs for non-muscle invasive bladder cancer (NMIBC): recommendations from the International Bladder Cancer Group (IBCG). *J Clin Oncol*. 2016;34(16):1935-1944.
23. Kamat AM, Hahn NM, Efsthathiou JA, et al. Bladder cancer. *Lancet*. 2016;388(10061):2796-2810.
24. Kamat AM, Witjes JA, Brausi M, et al. Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer. *J Urol*. 2014;192(2):305-315.
25. Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin. *Eur Urol*. 2016;69(1):60-69.
26. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. *Eur Urol*. 2006;49(3):466-477.
27. Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: Which patients benefit from the instillation? *Eur Urol*. 2016;69(2):231-244.
28. Kaasinen E, Rintala E, Hellström P, et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. *Eur Urol*. 2002;42(2):167-174.
29. Huncharek M, Geschwind JF, Witherspoon B, McGarry R, Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. *J Clin Epidemiol*. 2000;53(7):676-680.
30. Kamat AM, Flaig TW, Grossman HB, et al. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. *Nat Rev Urol*. 2015;12(4):225-235.
31. Kamat AM, Porten S. Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer. *Eur Urol*. 2014;65(2):267-269.
32. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. *Eur Urol*. 2013;63(3):462-472.
33. Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. *Eur Urol*. 2008;53(5):992-1001.



Navigating Precision Medicine In Bladder Cancer Optimizing the Identification and Selection of Patients for Immunotherapy

34. Lamm D, Persad R, Brausi M, et al. Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. *J Urol.* 2014;191(1):20-27.
35. Stimson CJ, Chang SS, Barocas DA, et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. *J Urol.* 2010;184(4):1296-1300.
36. Li R, Spiess PE, Kamat AM. Treatment options for patients with recurrent tumors after BCG therapy: Are we ignoring the obvious? *Eur Urol.* 2018 Oct;74(4):405-408.
37. Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. *Nat Rev Urol.* 2018 Jul 10. [Epub ahead of print] Review.
38. Nepple KG, Lightfoot AJ, Rosevear HM, O'Donnell MA, Lamm DL; Bladder Cancer Genitourinary Oncology Study Group. Bacillus Calmette-Guérin with or without interferon α -2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. *J Urol.* 2010;184(5):1915-1919.
39. Shepherd AR, Shepherd E, Brook NR. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer. *Cochrane Database Syst Rev.* 2017 Mar 8;3:CD012112. doi:10.1002/14651858.CD012112.pub2
40. Shore ND, Boorjian SA, Canter DJ, et al. Intravesical rAd-IFN α /Syn3 for patients with high-grade, Bacillus Calmette-Guérin-Refractory or relapsed non-muscle-invasive bladder cancer: A phase II randomized study. *J Clin Oncol.* 2017;35(30):3410-3416.
41. Packiam VT, Lamm DL, Barocas DA, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: Interim results. *Urol Oncol.* 2017 Jul 26. [Epub ahead of print]
42. Kowalski M1, Guindon J, Brazas L, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. *J Urol.* 2012;188(5):1712-1718.
43. Dickstein R, Wu N, Cowan B, et al. VISTA, Phase 3 Trial of Vicinium, an EpCAM-Targeted Pseudomonas Exotoxin, in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer. Global Congress on Bladder Cancer 2018, September 20-21, 2018; Madrid, Spain.
44. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. *Lancet.* 2016;387(10031):1909-1920.
45. Balar AV, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. *Lancet.* 2017;389(10064):67-76.
46. Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. *Lancet Oncol.* 2017;18(2):212-220.
47. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *N Engl J Med.* 2017;376(11):1015-1026.
48. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. *Lancet Oncol.* 2016;17(11):1590-1598.



Navigating Precision Medicine In Bladder Cancer

Optimizing the Identification and Selection of Patients for Immunotherapy

49. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. *J Clin Oncol*. 2016;34(26):3119-3125.
50. Apolo AB, Infante JR, Balmanoukian A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: Results from a multicenter, phase Ib study. *J Clin Oncol*. 2017;35(19):2117-2124.
51. Alfred Witjes J, Lebre T, Comp erat EM, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. *Eur Urol*. 2017;71(3):462-475.
52. Tecentriq (atezolizumab) prescribing information. Available at https://www.gene.com/download/pdf/tecentriq_prescribing.pdf. Accessed September 27, 2018.
53. Keytruda (pembrolizumab) prescribing information. Available at https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed September 27, 2018.
54. Efremova M, Finotello F, Rieder D, Trajanoski Z. Neoantigens generated by individual mutations and their role in cancer immunity and immunotherapy. *Front Immunol*. 2017;8:1679.
55. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. *Nature*. 2013;500(7463):415-421.
56. Perez-Gracia JL, Loriot Y, Rosenberg JE, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Outcomes by prior number of regimens. *Eur Urol*. 2017 Dec 19. [Epub ahead of print]
57. Powles T, Dur an I, Van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*. 2018;391(10122):748-757.
58. Opdivo (nivolumab) prescribing information. Available at https://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed September 27, 2018.
59. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. *Lancet Oncol*. 2017;18(3):312-322.
60. Imfinzi (durvalumab) prescribing information. Available at <https://www.azpicentral.com/imfinzi/imfinzi.pdf#page=1>. Accessed September 27, 2018.
61. Powles T, O'Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1/2 open-label study. *JAMA Oncol*. 2017;3(9):e172411.
62. Bavencio (avelumab) prescribing information. Available at <https://www.emdserono.com/content/dam/web/corporate/non-images/country-specifics/us/pi/bavencio-pi.pdf>. Accessed September 27, 2018.
63. Apolo AB, Ellerton J and Infante JR, et al. Avelumab treatment of metastatic urothelial carcinoma (mUC) in the phase 1b JAVELIN solid tumor study: updated analysis with 6 months of follow-up in all patients. *Ann Oncol*. 2017;28(Suppl. 5):300-301.
64. Vuky J, Balar AV, Castellano DE, et al. Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). *J Clin Oncol* 36, 2018 (suppl; abstr 4524).
65. U.S. Food & Drug Administration. FDA limits the use of Tecentriq and Keytruda for some urothelial cancer patients. Available at



Navigating Precision Medicine In Bladder Cancer

Optimizing the Identification and Selection of Patients for Immunotherapy

<https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm612484.htm>. Accessed September 27, 2018.

66. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. *Clin Cancer Res*. 2012;18(7):2039-2047.
67. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. *Nature*. 2014;515(7528):558-562.
68. Champiat S, Derclé L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. *Clin Cancer Res*. 2017;23(8):1920-1928.
69. Saâda-Bouزيد E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Ann Oncol*. 2017;28(7):1605-1611.
70. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res*. 2009;15(23):7412-7420.
71. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2018;36(17):1714-1768.
72. Pan K, Klapheke A, Cress R, Yap S. No improvement in metastatic bladder cancer health disparity over the last two decades [ASCO abstract e18076]. *J Clin Oncol*. 2017;35(15):e18076.
73. Weiner AB, Keeter MK, Manjunath A, Meeks JJ. Discrepancies in staging, treatment, and delays to treatment may explain disparities in bladder cancer outcomes: An update from the National Cancer Data Base (2004-2013). *Urol Oncol*. 2018 May;36(5):237.e9-237.e17.
74. Ramalingam SS. Lung cancer: disparities and implications for immunotherapy [AACR abstract IA24]. *Cancer Epidemiol, Biomarkers & Prevent*. 2016;25(3):IA24.
75. Committee on Improving the Quality of Cancer Care. Patient-centered communication and shared decision making. In: Levit L, Balogh E, Nass E, et al, eds. *Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis*. Washington, DC: National Academies Press; 2013.
76. Institute for Clinical Immuno-oncology (ICLIO). *Advancing Immuno-oncology in the Community Setting*. 2017. acc-iclio.org/wp-content/uploads/2016/01/ICLIO-White-Paper-Final.pdf. Accessed February 13, 2018.
77. Kane HL, Halpern MT, Squiers LB, Treiman KA, McCormack LA. Implementing and evaluating shared decision making in oncology practice. *CA Cancer J Clin*. 2014;64(6):377-388.
78. Politi MC, Studts JL, Hayslip JW. Shared decision making in oncology practice: what do oncologists need to know? *Oncologist*. 2012;17(1):91-100.